Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram
- PMID: 10731626
- DOI: 10.1016/S0893-133X(99)00148-7
Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is a recreational drug that has been shown to release serotonin (5-HT) and dopamine (DA) in animals. The effect of MDMA on 5-HT release can be blocked by 5-HT uptake inhibitors such as citalopram, suggesting that MDMA interacts with the 5-HT uptake site. It is unknown whether this mechanism is also responsible for the psychological effects of MDMA in humans. We investigated the effect of citalopram pretreatment (40 mg iv) on the psychological effects of MDMA (1.5 mg/kg po) in a double-blind placebo-controlled psychometric study in 16 healthy human volunteers. MDMA produced an emotional state with heightened mood, increased self-confidence and extroversion, moderate derealization, and an intensification of sensory perception. Most of these effects were markedly reduced by citalopram. This finding suggests that the psychological effects of MDMA are mediated via action at the 5-HT uptake site to increase 5-HT release through the carrier, as expected from animal studies.
Similar articles
-
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.J Psychopharmacol. 2000;14(3):269-74. doi: 10.1177/026988110001400313. J Psychopharmacol. 2000. PMID: 11106307 Clinical Trial.
-
Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.Neuropsychopharmacology. 2001 Mar;24(3):240-52. doi: 10.1016/S0893-133X(00)00199-8. Neuropsychopharmacology. 2001. PMID: 11166515
-
Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA).Hum Brain Mapp. 2001 Nov;14(3):152-65. doi: 10.1002/hbm.1049. Hum Brain Mapp. 2001. PMID: 11559960 Free PMC article. Clinical Trial.
-
Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.J Psychopharmacol. 2006 Mar;20(2):211-25. doi: 10.1177/0269881106059486. J Psychopharmacol. 2006. PMID: 16510479 Review.
-
Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').Drug Saf. 1996 Aug;15(2):107-15. doi: 10.2165/00002018-199615020-00003. Drug Saf. 1996. PMID: 8884162 Review.
Cited by
-
Characterization of the Neurochemical and Behavioral Effects of the Phenethylamine 2-Cl-4,5-MDMA in Adolescent and Adult Male Rats.Int J Neuropsychopharmacol. 2024 May 1;27(5):pyae016. doi: 10.1093/ijnp/pyae016. Int J Neuropsychopharmacol. 2024. PMID: 38546531 Free PMC article.
-
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?Neurotherapeutics. 2024 Mar;21(2):e00322. doi: 10.1016/j.neurot.2024.e00322. Epub 2024 Jan 25. Neurotherapeutics. 2024. PMID: 38278658 Free PMC article. Review.
-
Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use Is Related to Glutamate and GABA Concentrations in the Striatum But Not the Anterior Cingulate Cortex.Int J Neuropsychopharmacol. 2023 Jun 23;26(6):438-450. doi: 10.1093/ijnp/pyad023. Int J Neuropsychopharmacol. 2023. PMID: 37235749 Free PMC article.
-
The Altered States Database: Psychometric data from a systematic literature review.Sci Data. 2022 Nov 23;9(1):720. doi: 10.1038/s41597-022-01822-4. Sci Data. 2022. PMID: 36418335 Free PMC article.
-
Study protocol for "MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study".Front Psychiatry. 2022 Oct 26;13:954388. doi: 10.3389/fpsyt.2022.954388. eCollection 2022. Front Psychiatry. 2022. PMID: 36386973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
